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Menstrual cycle associated changes in hormone-related gene
expression in oestrogen receptor positive breast cancer
Ben P. Haynes1*, Ophira Ginsburg 2, Qiong Gao 3, Elizabeth Folkerd1, Maria Afentakis1, Richard Buus 1,3, Le Hong Quang4,
Pham Thi Han5, Pham Hong Khoa4, Nguyen Van Dinh 4, Ta Van To5, Mark Clemons6, Chris Holcombe7, Caroline Osborne8,
Abigail Evans9, Anthony Skene10, Mark Sibbering11, Clare Rogers12, Siobhan Laws13, Lubna Noor14, Ian E. Smith15 and
Mitch Dowsett 1,3
The major changes in hormone levels that occur through the menstrual cycle have been postulated to affect the expression of
hormone-regulated and proliferation-associated genes (PAGs) in premenopausal ER+ breast cancer. Whilst previous studies have
demonstrated differences in gene expression, here, we investigated if there are within patient changes in the expression of
oestrogen- and progesterone-regulated genes (ERGs and PRGs) and PAGs in ER+ breast cancer during the menstrual cycle. Samples
from 96 patients in two independent prospective studies of the effect of menstrual cycle on ER+ breast cancer were used. Plasma
hormone measurements were used to assign tumours to one of three pre-defined menstrual cycle windows: W1 (days 27–35 and
1–6; low oestradiol and low progesterone), W2 (days 7–16; high oestradiol and low progesterone) and W3 (days 17–26;
intermediate oestradiol and high progesterone). RNA expression of 50 genes, including 27 ERGs, 11 putative PRGs and seven PAGs
was measured. The AvERG (geomean of PGR, GREB1, TFF1 and PDZK1) was used as a composite measure of ERG expression and
showed significant changes between the three windows of the menstrual cycle increasing over 2.2-fold between W1 and W2 and
decreasing between W2 and W3 and between W3 and W1. Proliferation gene expression also varied significantly, following the
same pattern of changes as ERG expression, but the changes were of lower magnitude (1.4-fold increase between W1 and W2).
Significant changes in the expression of eight individual ERGs, including GREB1, PGR and TFF1, and two PAGs were observed
between W1 and either W2 or W3 with all genes showing higher levels in W2 or W3 (1.3–2.4-fold; FDR 0.016–0.05). The AvProg, a
composite measure of PRG expression, increased significantly (1.5-fold) in W3 compared to W1 or W2 but no significant changes
were observed for individual PRGs. In conclusion, we observed significant changes in ERG, PRG and PAG expression in ER+ breast
tumours during the menstrual cycle that may affect the assessment and interpretation of prominent biomarkers (e.g. PgR) and
commonly used multigene prognostic signatures in premenopausal ER+ breast cancer.
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INTRODUCTION
In premenopausal women, oestrogen receptor positive (ER+)
disease constitutes over 80% of breast cancers.1 The vast majority
of these patients will receive endocrine therapy, often by ovarian
ablation, although ER status is an imperfect predictor of response
to this therapy. In the postmenopausal setting, short-term
withdrawal of oestrogens using an aromatase inhibitor for two
weeks between a woman’s diagnosis and surgery has been used
to assess the oestrogen dependence of ER+ breast cancers.2–5
However, it is not feasible to conduct a similar pharmacological
pre-surgical test in premenopausal patients as the drugs used,
tamoxifen or gonadotrophin releasing hormone agonists, often
display early biochemical “flare” which would obscure molecular
changes over the first few weeks.6,7 As an alternative way of
measuring a tumour’s oestrogen-dependency in the premeno-
pausal setting, we hypothesised that if there are predictable and
consistent differences in the expression of oestrogen-regulated
genes (ERGs) and proliferation-associated genes (PAGs) in
hormone-responsive ER+ breast tumours in premenopausal
women due to the large variations in plasma concentrations of
oestrogen (c.100pM to c.1000pM) and progesterone (<3 nM to
>50 nM) during the menstrual cycle, the absence of such change
could signify hormone insensitivity. This was driven by the
observation that the expression of ERGs in ER+ breast tumours
correlated strongly with circulating levels of oestradiol in
postmenopausal women.8
In a retrospective study we found ERG expression to be
50–200% higher in mid- to late cycle (days 7–26), when oestrogen
levels are higher, compared to very late or earlier in the cycle (days
27–35 and 1–6) when oestrogen levels are lower.9 PAGs appeared
to have a lower level of expression in the progesterone-dominated
luteal phase of the cycle.10 We also demonstrated that RANKL
(TNFSF11), an archetypal progesterone-regulated gene (PRG),
increased over twofold in the luteal phase.
In addition to postulating that these differences in gene
expression in ER+ breast cancer might have the potential to be
used in an endogenous test of endocrine responsiveness we
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reasoned that hormone-dependent changes in gene expression
through the cycle could impact on the interpretation of commonly
measured biomarkers (e.g. PgR) and multigene prognostic
signatures (such as Oncotype DX Recurrence Score (RS), Prosigna
(PAM50), EndoPredict (EP) and Breast Cancer Index (BCI)).11–14
These signatures contain multiple ERGs and PAGs, whose
expression might vary in ER+ breast cancer according to when
during the menstrual cycle they are measured.
The earlier studies were retrospective in nature and limited to
cross-sectional comparisons between single samples from
patients in pre-defined windows of the menstrual cycle. As such,
while differences in tumoural gene expression through the cycle
were recorded, actual changes within patients could only be
implied and the variability between patients in any such changes
could not be assessed. Here we directly ask (i) whether the
differences noted previously are explained by consistent within
patient changes in gene expression through the phases of the
menstrual cycle and (ii) if these changes reflect the sensitivity of
the tumours to oestrogen-deprivation and therefore can predict
the antiproliferative response to ovarian ablation.
RESULTS
Patient demographics
Patient demographics are described separately for the two
independent prosepective studies in Supplementary Table 1. All
patients were ER+, 88% were PgR+ve and 9% HER2+ve; five of
the six HER2+ve cases were in the Vietnamese cohort.
Serum hormone levels
Serum hormone concentrations showed the expected patterns of
change during the menstrual cycle (Fig. 1a). Levels of oestradiol
were highest in W2 (median 845 pmol/L; 95% CI 413–991) with
little overlap of values in W1 (127 pmol/L; 95% CI 96–166);
concentrations in W3 (364 pmol/L; 95% CI 277–468) were
intermediate between those in W1 and W2 (Fig. 1b). There was
nearly complete separation of progesterone concentrations in W3
(21.5 nmol/L; 95% CI 12.1–30.1) from the low values in W1
(1.1 pmol/L; 95% CI 0.7–1.7) and W2 (1.7 pmol/L; 95% CI 0.8–2.3).
Sample availability
RNA was successfully extracted in paired tumour samples
(diagnosis and surgery) from 54 of the 70 patients recruited in
MenCER (Consort diagram, Supplementary Fig. 1). Nine of these
patients were excluded due to ambiguous menstrual cycle data.
Overall, 45 patients with good quality gene expression and
consistent menstrual cycle data were available. The median time
between the tumour samples was 27 days (interquartile range
20–34 days).
In the Vietnamese study, paired FFPE tumour samples at
diagnosis and two weeks later (prior to OvX) were available for 35
of 56 patients (Consort diagram, Supplementary Fig. 1). Of these,
RNA was successfully extracted for 27 sample pairs, seven of which
were excluded due to ambiguous menstrual cycle data, yielding a
final set of 20 patients. The median time between the tumour
samples was 9 days (interquartile range 8–13 days).
Combining samples from the two studies gave a final group of
65 patients with the following window comparisons available:
15 same window comparisons (all MenCER); 14 comparisons of W1
vs. W2 (7 MenCER, 7 Vietnamese); 20 comparisons of W2 vs. W3
(14 M, 6 V); 10 comparisons of W1 vs. W3 (7 M, 3 V); 28
comparisons of W1 vs. (W2 or W3) (14 M, 14 V); 32 comparisons
of (W1 or W2) vs. W3 (23 M, 9 V) (Supplementary Fig. 2,
Supplementary Data 1).
Unsupervised clustering of combined sample set
Unsupervised clustering of the gene expression data from this
combined sample set of 130 samples showed that 52 of the 65
paired samples clustered together. There were four main clusters
apparent, labelled A–D in Fig. 2. Cluster A was enriched for
samples taken in W3 (24% W1, 24% W2, 52% W3) and showed the
lowest relative expression of PAGs, high expression of most ERGs
and high PRG expression. Cluster B comprised a more evenly
mixed group of tumours from the three windows (36% W1, 32%
W2, 32% W3) and segregated from cluster A based on relatively
higher PAG and lower PRG expression. Clusters C and D differed
from the other clusters on the basis of their lower expression of
ERGs and PRGs and contained 94% (15/16) of the PgR -ve samples.
Cluster D was enriched for tumour samples taken in W2 (25% W1,
45% W2, 30% W3) and showed the highest relative expression of
PAGs and the lowest of PRGs and PGR (30% IHC PgR −ve). Overall,
in this combined dataset, PGR expression and the AvProg were
both inversely correlated to the expression of PAGs (Spearman r=
−0.29, p= 0.0007 and r=−0.36, p= 0.0007, respectively) (Sup-
plementary Fig. 3).
Fig. 1 Serum hormone levels in 65 patients assessable in pre-specified window comparisons, a smoothed median (±1 day) concentrations,
error bars indicate interquartile range, b comparison of oestradiol and progesterone concentrations between windows
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Comparison of gene expression changes in samples from the
same window of the menstrual cycle
We first assessed if there were any significant changes in gene
expression between the 15 tumour samples taken in the same
window of the menstrual cycle (but one cycle apart). Five of our
45 selected genes (GEM, NFKB1A, PTGS2, STAT5A, ZFP36)
increased significantly (1.6–4.4-fold; FDR 0.04 to 0.0025; Supple-
mentary Data 2, Supplementary Fig. 4) between diagnosis and
surgery. It appears that the upregulation of these genes may be
related to longer time to fixation for the surgical samples rather
than study-related as four of these genes were also up regulated
in our studies of changes in gene expression in the absence of
drug-treatment.15,16 These five genes were excluded from
further analysis, as any changes in their expression between
windows could not be ascribed with confidence to menstrual
cycle effects.
Gene expression changes during the menstrual cycle: individual
window comparisons
For the individual window comparison between W1 and W3 and
between W1 and W2, the sample size was small (n= 10 and 14
pairs respectively) and none of the changes in individual gene
expression reached significance after correction for multiple
testing (FDR < 0.05; Supplementary Data 2). However, for the
comparison between W1 and W2 whilst no gene had an FDR <
0.05, the four ERGs comprising the AvERG increased 1.9–2.7 fold in
W2 compared to W1 (uncorrected p-values 0.003 to 0.068, FDR
0.068 to 0.23). The expression of all seven PAGs also showed a
consistent trend to increase between W1 and W2 (FC 1.1–1.5;
uncorrected p-values 0.002 to 0.19, FDR 0.13 to 0.36; Supplemen-
tary Data 2).
Between W2 and W3 (n= 20 pairs), TFF1 and ATP6V1B1 both
decreased significantly (FC 0.47, BH= 0.008; FC 0.55, BH= 0.034,
respectively; Supplementary Data 2). Of note FKBP5, a putative
PRG, increased in 16 of the 20 tumours and this neared statistical
significance (FC 1.6, BH= 0.051). RANKL, which was expressed to a
very low extent, and other putative PRGs (RASSF5, EFHD1, TGFB3,
SGK3, SHROOM3, TNFSF10) did not consistently change between
W2 and W3.
The AvERG showed significant changes between the three
windows (Kruskal-Wallis p= 0.0002); increasing between W1 and
W2 (FC 2.2, p= 0.011), and decreasing between W2 and W3 (FC
0.62, p= 0.006) and between W3 and W1 (FC 0.58, p= 0.01) (Fig.
3). Proliferation gene expression (AvProlif), also varied significantly
(Kruskal-Wallis p= 0.012), increasing between W1 and W2 (FC
1.41, p= 0.035) with non-significant decreases thereafter between
W2 and W3 (FC 0.95, p= 0.50) and W3 to W1 (FC 0.74, p= 0.084).
The AvProg showed a numerically higher level in W3 compared to
the other windows but this did not approach statistical
significance (FC 1.2–1.6, p= 0.19–0.23; Fig. 3).
Gene expression changes during the menstrual cycle: Window 1
vs. Window 2 or 3
A pre-specified comparison of W1 vs. a combined W2 or W3 (n=
28) allowed for greater power for assessing the change from a low
to high/intermediate oestradiol exposure. The expression of 10
individual genes (eight ERGs and two PAGs) changed significantly
between W1 and W2 or W3, with all genes showing higher levels
in W2-W3 (FC 1.4–2.4; FDR 0.016–0.05; Supplementary Table 2).
Fig. 2 Unsupervised hierarchical clustering of gene expression data from the combined sample set of 130 samples (65 pairs)
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These genes included three of the four archetypal ERGs (GREB1,
PGR and TFF1) comprising the AvERG and five putative ERGs
(IGSF1, MSMB, SERPINA3, ATP6V1B1, CELSR2) whose expression was
previously shown to be down-regulated after OvX.17 IGSF1 and
MSMB showed the greatest magnitude of change between the
windows (FC 2.4 and 2.3-fold respectively). In agreement with the
gene expression data, mean protein levels of PgR increased
between W1 and W2 or W3 (18.3% increase, p= 0.0015, FDR
0.024; Supplementary Fig. 5) but this did not lead to a change in
PgR positive/negative status for any tumour. Protein levels of ER
and Ki67 did not show a statistically significant change between
W1 and W2 or W3 (p= 0.056, BH 0.11 and p= 0.33, BH= 0.42
respectively; Supplementary Fig. 5).
The AvERG (FC 1.9, p= 0.0005) and AvProlif (FC 1.3, p= 0.013)
increased significantly between W1 and W2-W3 (Fig. 4). The
AvProg response was more variable but there was a trend to
increase in W2-W3 (FC 1.4, p= 0.09). The changes in AvERG and
AvProlif showed a weak correlation but there was no obvious
relationship between AvProg and either AvERG or AvProlif
(Supplementary Fig. 6). Individually the genes comprising the
AvERG increased approximately twofold in W2-W3 compared to
W1 (FC 1.7–2.2; BH 0.011–0.06) (Fig. 4). A similar pattern was
observed for PAGs with the exception of AURKA, although the
change was not as large (FC 1.3–1.5, BH 0.035–0.11) (Fig. 4).
Correlation of response to oestrogen deprivation with the change
in AvERG between W1 vs. W2-W3
There was no correlation of the response to OvX in the
Vietnamese study, as measured by % change in Ki67 (r=−0.30,
p= 0.32) or AvProlif (r=−0.05, p= 0.89), with the change in
AvERG between W1 vs. W2–W3 in the small group of patients
in which this could be compared (n= 12–13) (Fig. 5). Anecdotally,
there was only one clear HER2-ve non-responder to OvX by
Ki67 and this showed the least increase in AvERG between W1
vs. W2-W3.
Gene expression changes during the menstrual cycle: Window 3
vs. Window 1 or 2
The effects of the higher level of progesterone in W3 (roughly
corresponding to the luteal phase) compared to the rest of the
cycle were examined by comparing gene expression changes
between W3 vs. a combined W1 or W2 (n= 32) (Supplementary
Table 3, Supplementary Fig. 7). For this comparison, FKBP5, a
putative PRG, was the most significant gene and showed the
greatest fold-change (FC 1.5, p= 0.0057, BH= 0.23), increasing in
24 of 32 tumours in W3. RANKL was the 5th most significant gene
and showed the second greatest increase (FC 1.4, p= 0.10, BH=
0.65). Other putative PRGs changed to a lesser extent and with less
Fig. 3 Changes in AvERG, AvProlif and AvProg between individual windows (FC; fold-change). Dotted red lines indicate change in mean level
between compared windows. Error bars indicate mean ± 95% CI
B.P. Haynes et al.
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significance. Overall, AvProg increased significantly in W3 (FC 1.5,
p= 0.026) but there were no significant changes in AvERG or
AvProlif. The change in AvProg showed a borderline significant
correlation with PGR expression (r= 0.34, p= 0.06), such that the
tumours with higher PGR expression showed a greater change in
AvProg.
Unpaired analysis of differences in gene expression through
menstrual cycle
To determine the consistency of these data with our earlier cross-
sectional analysis we performed an exploratory unpaired analysis
of all samples assessing the differences in gene expression
between the three pre-defined windows (103 samples; 29 in W1,
37 in W2, 37 in W3). The AvERG showed significant differences
between the three windows (KW p= 0.0014) with the highest
level in W2; W1 vs. W2 (FC 2.2; p= 0.0005), W2 vs. W3 (FC 0.63,
p= 0.015), W1 vs. W3 (FC 0.73, p= 0.14) (Fig. 6). The AvProlif
showed a trend to increase between W1 and W2 (FC 1.3, p= 0.07)
and there was a strong trend for the AvProg to be higher in W3;
W2 vs. W3 (FC 1.5, p= 0.056), W1 vs W3 (FC 0.66, p= 0.07).
Hierarchical clustering of the unpaired gene expression data
according to the window in which the sample was taken further
illustrates the differences in gene expression between windows
and also demonstrates the large variation that occurs within each
window (Supplementary Fig. 8).
DISCUSSION
We have previously reported significant differences in the
expression of ERGs, PAGs and the PRG, RANKL, in ER+ tumours
in a retrospective study that related to the major changes in
hormone levels that occur during the menstrual cycle.9,10 Here, we
have extended that observation in a prospective study to show
significant changes of gene expression of ERGs, PRGs and PAGs
within individual patients through the menstrual cycle and the
degree of variability in these changes between patients.
Previous work investigating changes in breast tumour biology
during the menstrual cycle is limited and the data are very
variable18–25 which is most likely due to difficulties and differences
in assigning the phase of menstrual cycle. Here, both serum
hormone concentrations and menstural cycle data were used to
improve the definition of times through the mentrual cycle and to
assign patients to one of three pre-defined menstrual cycle
windows. Approximately 20% of cases were excluded due to
inconsistent menstrual cycle data. Windows 1 and 2 had low and
high E2 levels, respectively (up to a sevenfold difference) and very
low progesterone levels; window 3, which largely represents the
luteal phase, had mean levels of E2 intermediate between those of
windows 1 and 2 and up to 20-fold higher levels of progesterone.
We combined tumour samples from patients in two indepen-
dent trials to increase the power of the study as individually the
separate studies would have been too small to reach meaningful
conclusions. Whilst the trials had some differences in their design
and patient demographics, unsupervised clustering of the gene
expression data generated did not reveal any clear study-related
effects.
Tumour samples taken in the same window of the menstrual
cycle provided a control group and indicated that the expression
of five of our selected genes increased between diagnosis and
surgery irrespective of cycle window. The upregulation of these
genes does not appear to be study-related as four of these genes
Fig. 4 Changes in AvERG, AvProlif and AvProg and in expression of their individual component ERGs, PAGs and PRGs between Window 1 vs.
Windows 2 or 3 (n= 28)
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were also upregulated in studies of changes in gene expression in
the absence of drug-treatment15,16 where the upregulation was
ascribed to differences in the time taken to fixation for the
samples at the two time points. These five genes were thus
excluded from further analysis, as any changes in their expression
between different windows would not be attributable to
menstrual cycle effects.
Unsupervised clustering of the gene expression data from all
samples showed that most pairs clustered together indicating that
the changes in gene expression during the menstrual cycle were
not as great as the variation between patients in the majority of
cases. Nonetheless, the clustering revealed contrasting clusters
enriched for tumours taken in W2 and W3 indicating the timing of
the menstrual cycle had some effect on the clustering. The cluster
enriched for W2 tumours showed the highest relative expression
of PAGs and the lowest of PRGs while the cluster enriched for W3
tumours showed the lowest relative expression of PAGs and high
PRG expression. This was reflected by an inverse correlation
between both PGR expression and signalling and proliferation
across all samples. These data are consistent with progesterone
receptor signalling modulating oestrogen-driven proliferation in
this premenopausal setting. The concept that PR activation in the
context of oestrogen-driven, ER+ breast cancer, can have an anti-
proliferative effect has been postulated by others26,27 and it seems
that the oestrogenic status can directly affect whether progesto-
gens are pro-proliferative or antiproliferative. Thus, in the absence
of a functional oestrogen-activated ER complex, PgR activation
can stimulate proliferation28–30 but when oestrogen and a
progestogen are combined, reductions in the oestrogen-induced
growth response have been reported both in vitro28,31 and
ex vivo.26 Mechanistically, it appears that in the presence of both
oestrogen and progesterone ligands, PR can affect ER target gene
activity by altering the interaction between ER and chromatin
thereby changing the transcriptional output of the ER
complex.26,27
The comparison of gene expression between W1 (low
oestradiol) with W2 (high oestradiol) was the most biologically
straightforward window comparison in terms of hormone levels
and this revealed a strong trend for an increase in ERG expression
between W1 and W2. Thus, the four ERGs comprising the AvERG (a
pre-defined composite measure of ERG expression) all increased
two to threefold in W2 compared to W1 but this did not reach
statistical significance most likely due to the small sample size
available. Comparison of W2 and W3 is less straightforward to
interpret as changes could be due to either the lower oestradiol
levels (approximately 50%), or the much higher progesterone
levels in W3 (>10-fold) or both; the only two genes that changed
significantly were ERGs (TFF1, ATP6V1B1) which both decreased by
approximately 50% in W3. The AvERG, showed significant changes
between the three individual windows with a mean increase of
220% between W1 and W2 and approximate 40% decreases
thereafter between W2 and W3 and between W3 and W1.
To increase the power to detect changes in gene expression
from a low to high/intermediate oestradiol exposure we
performed a pre-specified comparison of W1 vs. a combined W2
or W3. This showed that the expression of eight ERGs significantly
increased (mean of 1.9-fold) between W1 and W2 or W3 including
three of the four ERGs (GREB1, PGR and TFF1) comprising the
AvERG. Similar to our earlier retrospective study,9,10 the fourth
gene comprising the AvERG, PDZK1, did not show a significant
change in expression although it showed a strong trend to do so.
This is in agreement with a recent study which showed a
correlation of GREB1, PGR and TFF1 but not PDZK1 gene expression
in ER +ve tumours with serum oestradiol levels in premenopausal
patients.32 This latter study concurred with our earlier cross-
sectional study but lacked the longitudinal aspect of the current
study to allow consideration of within patient changes. Overall,
the AvERG showed a near twofold increase in expression between
W1 and W2 or W3. This compared to a difference of 1.5-fold
between the same windows in the retrospective study.9,10 Of the
other putative ERGs that changed significantly between W1 and
W2 or W3, IGSF1, a member of the immunoglobulin-like domain-
containing superfamily and MSMB, an immunoglobulin binding
factor showed the greatest magnitude of change. Both of these
genes have been reported to have inhibin activity,33,34 which may
be a factor in their increase in expression in W2–W3 vs. W1.
An unpaired analysis to assess differences rather than changes
in gene expression between the three pre-defined windows
demonstrated that the AvERG showed significant differences
between all windows, mirroring the paired changes reported
above, and these showed the same pattern to the previous cross-
sectional retrospective study.9,10
The expression of PAGs across the menstrual cycle mirrored the
changes observed in ERG expression but the magnitude of effect
was less. Thus, between W1 and W2, individual PAGs showed a
trend to increase between W1 and W2 such that the AvProlif, a
pre-defined composite measure of PAG expression, showed
significant changes between the three windows characterised
Fig. 5 Correlation of change in AvERG during menstrual cycle (Window 1 vs. Windows 2 or 3) with % change in Ki67 (a) and % change in
AvProlif (b) after OvX; • HER2+ ve tumours
B.P. Haynes et al.
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particularly by a mean increase of 40% between W1 and W2.
Comparison of W1 vs. W2 or W3 revealed significant increases in
the expression of two individual PAGs and a 30% increase of the
AvProlif in W2 or W3 compared to W1. These data are in slight
contrast to our earlier report of lower PAG expression in W3 with
no difference between W1 and W2.9,10 However, the unpaired
analysis of the current data demonstrated a very similar pattern of
expression of AvProlif to the previous retrospective study with a
decline in proliferation at the end of W2 (days 13–16) such that
the AvProlif is near its nadir at the start of W3.
The RANK signalling pathway is known to be a key paracrine
mediator of progestogen action in breast epithelium and its
protein expression has been shown to correlate with serum
progesterone levels.35,36 We previously reported twofold higher
levels of RANKL in W3, roughly corresponding to the luteal phase
of the menstrual cycle, when progesterone levels are at their
highest, compared to the other windows10 and this has also been
observed by others.37 Here, we measured RANKL and 10 other
putative PRGs to investigate if changes in their expression during
the menstrual cycle were apparent and used the AvProg as a
composite measure of PRG gene expression. Whilst the number of
samples available between W1 and W3 was too small to detect
any significant changes in individual gene expression, comparison
of W2 and W3 showed that FKBP5 increased in 80% of the tumours
in W3 and this was borderline significant. However, RANKL itself
did not show an increased level of expression in W3, possibly
because it was expressed to a very low extent in this group of
tumours. The AvProg did not show any significant changes
between the individual windows but showed a trend to increase
in W3 compared to the other windows. A comparison of W3 with a
combined W1 or W2 increased the power to compare the effects
of a high progesterone milieu in W3 with the much lower
progesterone levels in W1 or W2 and demonstrated that the
AvProg increased significantly in W3 as would be expected due to
the much higher level of progesterone in W3 compared to the rest
of the cycle. These changes in PRGs were more modest than those
in ERG and PAG expression across the cycle as a whole.
In order to investigate if the changes in gene expression in ER+
breast cancer during the menstrual cycle we report here could
predict the antiproliferative response to ovarian ablation we
correlated the change in AvERG between W1 and W2 or W3 with
the response to OvX in samples from the Vietnamese study.17
Only a very weak correlation was observed. Although this analysis
had only low power due to the small number of samples available,
even with this small number it appears that this putative
endogenous test of hormonal sensitivity could not be sufficiently
reliable for clinical use.
The main weakness of the current work was the relatively low
proportion of patients available for comparisons of the individual
windows of the menstrual cycle, even after combining patient
samples from two independent studies. Combining windows
enabled greater power but in some cases (e.g. combining W2 and
W3) also added possible confounding factors such as widely
differing progesterone concentrations within the combined
window. Despite this, the impact of changes in endogenous
reproductive hormones on gene expression was demonstrated
very clearly.
The multigene prognostic signatures which are commonly used
in ER+ breast cancer such as RS, PAM50, EP and BCI,11–14 contain
mulitple ERGs and PAGs and it is well established that the
expression of these genes are two of the main drivers of the
scores obtained from these tests.38 Thus, the possibility that
the hormonal changes during the menstrual cycle could affect the
read out from these signatures merits study and we are
investigating this hypothesis in a follow-up study.
In conclusion, our data indicate that there are significant
changes in ERG, PRG and PAG expression in line with the
hormone changes that occur during the menstrual cycle. These
Fig. 6 Differences in AvERG, AvProlif and AvProg during the menstrual cycle (n= 103, unpaired); smoothed median (±1 day) values, error bars
indicate interquartile range, red lines show mean (±95% confidence interval) of each window
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changes need to be noted in any studies of the hormone-related
biology of breast cancer in premenopausal patients and may
affect the interpretation of data from some of the multigene
prognostic signatures which are commonly used in ER+ breast
cancer.
METHODS
Patients and study designs
Patients were drawn from two prospective studies that assessed the
possible impact of the menstrual cycle on breast tumour biology in ER+
breast cancer. The first of these was MenCER (The Menstrual cycle as a test
of endocrine responsiveness in premenopausal breast cancer), a UK-based
multicentre study. In addition, menstrual cycle effects were studied in
patients from a study of neoadjuvant oophorectomy (OvX) in Vietnam. The
endocrine and molecular effects of OvX in this Vietnamese study have
been recently published.17
For the MenCER study, premenopausal women aged <50 years old with
histologically confirmed ER+ breast cancer who were proceeding to
surgery with no pre-surgical therapy, had a regular menstrual cycle and
had not received previous cancer therapy were eligible. Ethical approval
for the study was received from the local research ethics committee (South
West London REC 3). All participants provided written informed consent.
Paired blood and tumour samples were taken both at diagnosis and at
surgery with no treatment occurring between these time-points. Patient
reported date of last menstrual period and length of cycle were recorded.
The timing of surgery in relation to menstrual cycle was not controlled in
any way and it was expected that the menstrual phase at the time of
diagnosis and surgery for any given subject would be a chance event. We
also reasoned that the time between diagnosis and surgery would be
approximately two weeks and therefore in most patients would involve
different parts of their menstrual cycle. An accrual target of 70 patients was
selected on the basis of power calculations based on the magnitude of
changes (twofold) in ERGs we observed in our previous retrospective
studies.9,10 With 70 paired comparisons between the groups it would be
possible to detect a standardised difference of 0.5 between the groups for
each of the biomarkers with 80% power, and a standardised difference of
0.6 with 90% power.
The Vietnamese study was a single arm study of neoadjuvant OvX in
patients with ER+ breast cancer, details of which have been described
previously.17 In brief, the study recruited 56 premenopausal women with
ER+ breast cancer for whom modified radical mastectomy and surgical
bilateral salpingo-oophorectomy was planned as part of their breast cancer
treatment. Patients had to report regular menstrual cycles and must not
have received any prior chemotherapy or radiotherapy for their cancer.
The study was approved by the Institutional Ethics Committee of the
National Cancer Hospital, Hanoi, Vietnam from where all study participants
were recruited and by the Research Ethics Board of the University of
Toronto, Canada, from where the study was coordinated. The Committee
for Clinical Research at the Royal Marsden Hospital, London approved the
analysis of the samples collected in this trial. All participants provided
written informed consent. Breast tumour core biopsies (formalin fixed and
paraffin embedded) taken at diagnosis (A) and intra-operatively at the time
of OvX (B; 2 weeks later) were used in the current study. No treatment
occurred between these time-points. A single blood sample taken pre-OvX
(on day of OvX prior to anaesthesia or pre-operative medication; timepoint
B) was available for hormone measurements. Similar to the MenCER study,
the timing of surgery in relation to menstrual cycle was not controlled.
Exclusion criteria for both studies included: metastatic disease, use of
oral contraceptives or other hormonal contraceptives and concomitant use
of medications known to influence oestrogen levels. Informed consent was
obtained from all participants.
Serum hormone measurements
Serum concentrations of oestradiol (E2) were measured by radioimmu-
noassay following pre-assay purification using an organic extraction as
described previously.39,40 Progesterone was measured using a solid phase
radioimmunoassay (Beckman Coulter IM1188). LH and FSH were measured
using immunoradiometric assays (IBL International MG12151 and Dia-
source KIP0841 respectively). The serum hormone measurements were
used in combination with menstrual cycle information to ascribe patients
to one of three pre-defined menstrual cycle windows prior to considera-
tion of the biomarker data: window 1 (W1; low oestrogen and
progesterone milieu) days 27–35 or 1–6; window 2 (W2; high oestrogen
and low progesterone milieu) days 7–16; window 3 (W3; intermediate
oestrogen and high progesterone milieu) days 17–26 (Supplementary Fig.
2). In six patients one of the sample pairs fell on the cusp of two windows
(two between W1 and W2, four between W2 and W3; Supplementary Data
1); these samples were not used in the individual window comparisons but
were included when W1 and W2 or W2 and W3 were combined.
Immunohistochemistry
Hematoxylin and eosin sections were prepared for all FFPE tumour
samples and were reviewed to confirm diagnosis and assess tumour
content. Samples with tumour content <40% were excluded from further
analysis. Immunohistochemistry (IHC) and scoring for ER, PgR and Ki67
were performed as reported previously.41,42 ER and PgR were considered
positive if ≥1% cells stained positive. HER2 was measured immunohisto-
chemically using the HercepTest (DakoCytomation) and by fluorescent
in situ hybridization (Vysis Pathvysion, Downers Grove, IL) according to
manufacturer’s instructions. HER2 was considered positive if immunohis-
tochemical staining was scored 3+ or 2+ if the fluorescence in situ
hybridization analysis indicated an amplification ratio of >2.0.41
Gene selection
Selection of genes for analysis in the biopsies was based on the set of
genes we measured previously in a retrospective cross-sectional study.10
This previous set of genes comprised ESR1, 26 ERGs and putative ERGs that
correlated with variations in plasma E2 concentrations, seven PAGs and a
single PRG, RANKL. ERGs whose expression did not differ in the
retrospective study were replaced with 16 other ERGs and putative ERGs
based on the observation that they were the most highly up or down-
regulated after OvX.17 For the PAGs, we selected four of those measured
previously plus three other PAGs that were the most down-regulated after
OvX. In addition to RANKL, we selected 10 other putative PRGs for
measurement based on commonality in at least two literature reports26,43–48
and Mohammed20 personal communication. In total, 45 genes of interest
(18 genes in common with the previous study10) were selected for gene
expression measurement (Table 1). We used the AvERG (average ERGs; the
geomean of PGR, GREB1, TFF1 and PDZK18) as a composite measure of ERG
expression, the AvProlif (average PAGs; geomean of AURKA, CDC20, MKI67,
TOP2A, UBE2C) as a composite measure of PAGs and the AvProg (average
PRGs; geomean of FKBP5 and RANKL) as a composite measure of PRG
expression. We also measured five housekeeping genes (ACTB, MRPL19,
PSMC4, SF3A1, TBP).
Measurement of gene expression
Total RNA was extracted from two 10 μm sections of formalin-fixed
paraffin-embedded breast tumour samples using the RecoverAll (Ambion)
kit according to the manufacturer’s procedure. The NanoString nCounter
gene expression system (GEN2) (NanoString Technologies, Seattle, WA)
was used to measure gene expression without target amplification.49 In
brief, an nCounter CodeSet (NanoString Technologies) containing gene-
specific probe-pairs for the 50 genes selected above (including the five
housekeeping genes) as well as six exogenous positive control RNA
targets, and eight exogenous negative control sequences, was hybridised
to 200 ng total RNA in a single 30 μl hybridization reaction. After overnight
hybridization (15–21 h) at 65 °C, the samples were processed using the
NanoString nCounter Prep Station and Digital Analyzer according to the
manufacturer’s instructions. Assay validity was confirmed by assessing the
linearity of six internal positive RNA controls and the non-specific
background from signal in eight internal negative controls included in
each reaction. The raw nCounter counts for each gene of interest were
corrected for background by subtracting the geometric mean of the
negative controls, normalised to the geometric mean of the five
housekeeping genes to allow for variation in the amount and quality of
input RNA and log2 transformed (Supplementary Data 1; raw gene
expression data; Supplementary Data 3; normalised log-transformed data).
The housekeeping genes did not show any significant changes in
expression between individual windows or between the combinations of
windows (Supplementary Table 4).
Data analysis
For paired data, we performed pre-specified analyses of changes in the
gene expression levels between individual windows (W1 vs. W2, W2 vs. W3,
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W3 vs. W1) and combinations of windows (W1 vs. [W2 or W3]; [W1 or W2]
vs. W3) using the Wilcoxon matched pairs signed rank test. For unpaired
data, differences in gene expression between the three windows were
compared using the Kruskal-Wallis test and differences in gene expression
levels between the specific windows were assessed using the Mann
Whitney test (Graphpad Prism 7). To calculate the AvERG, AvProlif and
AvProg the geometric mean of the individual gene expression values of
the indicated genes was taken and log-transformed. For individual genes
the Benjamini–Hochberg procedure was used to the calculate false
discovery rate (FDR) in order to adjust for multiple testing.

















ACOX2 x x x
AGR2 x x x
ATP6V1B1 x x x
CELSR2 x x




GREB1 x x x
IGSF1 x x x
IRS1 x x x
MSMB x x x
MYB x x
NDP x x
PDZK1 x x x
PDZK1P1 x x x
PGR x x x
PTGS2 x x
RUNX1 x x x
SERPINA3 x x x
SERPINA5 x x x
SLC2A3 x x
STC2 x x x
TFF1 x x x
TFF3 x x x
TGFB3 x x x











TNFSF10 x x x
AURKA x x
CDC20 x x x
MKI67 x x x
TOP2A x x x
HMMR x x
UBE2C x x x
UBE2T x x x
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Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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